At a glance
ClinicalIndex Comparison RecordN/ACompleted· 3,330 enrolled
Drug / intervention
ABSORB Scaffolddevice
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
German-Austrian Register to Evaluate the Short and Long-term Safety and Therapy Outcomes of the ABSORB Everolimus-eluting Bioresorbable Vascular Scaffold System in Patients With Coronary Artery Stenosis
In Brief
An observational study evaluating ABSORB Scaffold for Coronary Artery Stenosis. Completed, enrolled 3,330 participants across 81 sites in 2 countries.
Detailed Summary
The German-Austrian ABSORB Register shall provide an analysis of acute and long-term safety as well as therapy outcomes of the ABSORB (trade mark) bioresorbable vascular scaffold system in patients suffering from coronary artery disease.
Study Details
Study Typeobservational
Allocation--
Masking--
Primary Purpose--
ConditionsCoronary Artery Stenosis
CountriesAustria, Germany
CollaboratorsAbbott Medical Devices
Timeline
N/ACompletedFinished
2014201520162017201820192020202120222023202420252026
Enrollment StartNov 2013
First PostedFeb 2014
Primary CompletionJan 2016
Study CompletionJul 2021
TodayJul 2026
First PostedFeb 19, 2014
Enrollment StartNov 8, 2013
Primary CompletionJan 31, 2016
Study CompletionJul 6, 2021
TodayJul 2, 2026
Enrollment to primary: 2.2 yearsPosted 12.4 years ago
Interventions
ABSORB Scaffolddevice
Implantation of a drug-eluting vascular scaffold, which is completely resorbable to improve the blood flow in coronary arteries in the presence of stenosis